11/16/2026 | Press release | Distributed by Public on 11/16/2026 13:11
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of the financial condition and results of operations of Adia Nutrition, Inc.. and its consolidated subsidiaries (collectively, the "Company") should be read in conjunction with our condensed consolidated financial statements and the accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q. References in this Management's Discussion and Analysis of Financial Condition and Results of Operations to "us," "we," "our," and similar terms refer to the Company. This Quarterly Report on Form 10-Q includes forward-looking statements, as that term is defined in the federal securities laws, based upon current expectations that involve risks and uncertainties, such as plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. Words such as "anticipate," "estimate," "plan," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could," and similar expressions are used to identify forward-looking statements.
We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence the accuracy of the statements and the projections upon which the statements are based. Reference is made to the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on March 31, 2026.
Results of Operations
For the nine months ended September 30, 2026 and 2025
Revenue
For the nine months ended September 30, 2026 and 2025, the Company revenues of $1,019,245 and $521,958, respectively. Revenue was generated from the following sources:
| For the nine months ended | For the nine months ended | |||||||||||||||
| September 30, 2026 | September 30, 2025 | |||||||||||||||
| Sales of supplements | $ | - | 0.0% | $ | 3,393 | 0.7% | ||||||||||
| Medical procedures | 576,770 | 56.6% | 198,600 | 38.0% | ||||||||||||
| Sales of biologics | 433,260 | 42.5% | 313,010 | 60.0% | ||||||||||||
| Services | - | - | 2,267 | 0.4% | ||||||||||||
| Shipping and delivery | 9,215 | 0.9% | 4,688 | 0.9% | ||||||||||||
| Total Revenue | $ | 1,019,245 | 100.0% | $ | 521,958 | 100.0% | ||||||||||
Gross Profit
For the nine months ended September 30, 2026 and 2025, cost of revenue was $544,907 and $278,497, respectively. Cost of revenue was as a result of the following:
| For the nine months ended | For the nine months ended | |||||||||||||||
| September 30, 2026 | September 30, 2025 | |||||||||||||||
| Cost of supplements | $ | - | 0.0% | $ | 1,057 | 0.4% | ||||||||||
| Cost for administration of medical procedures | 160,674 | 29.5% | 93,315 | 33.5% | ||||||||||||
| Cost of biologics | 384,233 | 70.5% | 184,125 | 66.1% | ||||||||||||
| Total Cost of Revenue | $ | 544,907 | 100.0% | $ | 278,497 | 100.0% | ||||||||||
As a result, our gross profit for the nine months ended September 30, 2026 and 2025, was $474,338 and $243,461, respectively.
Operating Expenses
For the nine months ended September 30, 2026 and 2025, we incurred total operating expenses of $710,379 and $391,390. The following is a tabular breakdown of our operating expenses for the nine months ended September 30, 2026 and 2025:
|
For the nine months ended September 30, |
||||||||
| 2026 | 2025 | |||||||
| Operating Expenses | ||||||||
| General and administrative | $ | 90,187 | $ | 129,119 | ||||
| Advertising and promotion | 75,843 | 54,979 | ||||||
| Clinical trial fees | 16,275 | - | ||||||
| Corporate filing fees | 17,299 | - | ||||||
| Equipment leases | 21,338 | 20,088 | ||||||
| Legal and professional fees | 236,323 | 104,976 | ||||||
| Public relations | 7,320 | - | ||||||
| Repairs and maintenance | 2,638 | - | ||||||
| Rent | 52,749 | 48,242 | ||||||
| Research and development | 4,375 | 30,808 | ||||||
| Salaries and wages | 177,263 | - | ||||||
| Utilities | 4,428 | - | ||||||
| Depreciation and amortization | 4,341 | 3,178 | ||||||
| Total Operating Expenses | $ | 710,379 | $ | 391,390 | ||||
Other Income (Expenses)
For the nine months ended September 30, 2026 and 2025, we had other income of $875 and $250, respectively. For the nine months ended September 30, 2026 and 2025, we had other expenses of $36,756 and $22,160, respectively. For the nine months ended September 30, 2026, other income was comprised of interest income on a loan we extended to a start-up facility. For the nine months ended September 30, 2026 and 2025, other expenses were comprised of interest expenses on our line of credit facility with a related party.
For the three months ended September 30, 2026 and 2025
Revenue
For the three months ended September 30, 2026 and 2025, the Company revenues of $454,385 and $332,048, respectively. Revenue was generated from the following sources:
| For the three months ended | For the three months ended | |||||||||||||||
| September 30, 2026 | September 30, 2025 | |||||||||||||||
| Sales of supplements | $ | - | 0.0% | $ | 1,238 | 0.4% | ||||||||||
| Medical procedures | 238,900 | 52.6% | 101,900 | 30.7% | ||||||||||||
| Sales of biologics | 211,735 | 46.6% | 225,510 | 67.9% | ||||||||||||
| Services | - | - | - | - | ||||||||||||
| Shipping and delivery | 3,750 | .8% | 3,400 | 1.0% | ||||||||||||
| Total Revenue | $ | 454,385 | 100.0% | $ | 332,048 | 100.0% | ||||||||||
Gross Profit
For the three months ended September 30, 2026 and 2025, cost of revenue was $233,404 and $128,563, respectively. Cost of revenue was as a result of the following:
| For the three months ended | For the three months ended | |||||||||||||||
| September 30, 2026 | September 30, 2025 | |||||||||||||||
| Cost of supplements | $ | - | 0.0% | $ | 395 | 0.3% | ||||||||||
| Cost for administration of medical procedures | 7,124 | 3.1% | 22,528 | 17.5% | ||||||||||||
| Cost of biologics | 226,280 | 96.9% | 105,640 | 82.2% | ||||||||||||
| Total Cost of Revenue | $ | 233,404 | 100.0% | $ | 128,563 | 100.0% | ||||||||||
As a result, our gross profit for the three months ended September 30, 2026 and 2025, was $220,981 and $203,485, respectively.
Operating Expenses
For the three months ended September 30, 2026 and 2025, we incurred total operating expenses of $260,131 and $124,285. The following is a tabular breakdown of our operating expenses for the nine months ended September 30, 2026 and 2025:
|
For the three months ended September 30, |
||||||||
| 2026 | 2025 | |||||||
| Operating Expenses | ||||||||
| General and administrative | $ | 33,234 | $ | 56,707 | ||||
| Advertising and promotion | 16,400 | 23,794 | ||||||
| Clinical trial fees | 4,250 | - | ||||||
| Corporate filing fees | 5,571 | - | ||||||
| Equipment leases | 7,946 | 8,928 | ||||||
| Legal and professional fees | 75,592 | 11,162 | ||||||
| Public relations | 2,400 | - | ||||||
| Repairs and maintenance | 476 | - | ||||||
| Rent | 16,818 | 16,240 | ||||||
| Research and development | 4,375 | 6,192 | ||||||
| Salaries and wages | 89,532 | - | ||||||
| Utilities | 1,890 | - | ||||||
| Depreciation and amortization | 1,647 | 1,262 | ||||||
| Total Operating Expenses | $ | 260,131 | $ | 124,285 | ||||
Other Income (Expenses)
For the three months ended September 30, 2026 and 2025, we had other income of $125 and $250, respectively. For three months ended September 30, 2026 and 2025, we had other expenses of $13,990 and $9,074, respectively. For the three months ended September 30, 2026, other income was comprised of interest income on a loan we extended to a start-up facility. For the nine months ended September 30, 2026 and 2025, other expenses were comprised of interest expenses on our line of credit facility with a related party.
Liquidity and Capital Resources
For the nine months ended September 30, 2026, we had a net loss of $271,922. For the nine months ended September 30, 2026, we had non cash charges of $4,341 in depreciation, $42,215 in amortization of operating lease right-of-use asset, and $17,747 in the amortization of finance lease right-of-use asset. For the nine months ended September 30, 2026, we had an increase in accounts receivable of $20,500, an increase in inventory of $323,475, an decrease in pre-paid expenses of $5,197, a increase in undeposited funds of $4,900, a decrease in receivable on sale of inventory asset of $376, an increase in accounts payable of $190,412, an increase in accrued interest on our line of credit of $36,757, an increase in deferred revenue of $126,300, and a decrease in operating lease liabilities of $42,201. As a result, we had net cash used in operating activities of $239,653 for the nine months ended September 30, 2026.
For the nine month ended September 30, 2025, we had a net loss of $169,839. For the nine months ended September 30, 2025, we had non cash charges of $3,178 in depreciation and amortization, $39,075 in amortization of operating lease right-of-use asset, and $12,683 in the amortization of finance lease right-of-use asset. For the nine months ended September 30, 2025, we had an increase in accounts receivable of $105,721, a decrease in inventory of $99,168, a decrease in pre-paid expenses of $25,667, a decrease in accounts payable of $2,504, an increase in accrued interest on our line of credit of $22,159, and a decrease in operating lease liabilities of $32,540. As a result, we had net cash used in operating activities of $108,521 for the nine months ended September 30, 2025.
Investing Activities
For the nine months ended September 30, 2026, we purchased additional equipment in the amount of $15,436, and provided additional funds to clinics in the amount of $5,300. As a result, we had net cash used in investing activities of $20,736.
For the nine months ended September 30, 2025, purchase additional furniture and equipment in the amount of $13,199, provided funds to start-up clinic operations in the amount of $25,000, and we disposed of the Biolete trademarks totaling $5,611. As a result, we had net cash used in investing activities of $32,588.
Financing Activities
For the nine months ended September 30, 2026, we made payments on our finance lease obligation of $16,497, and we drew down on our line of credit facility for an additional $335,312, and we had proceeds from the sale of a membership interest in our Adia Labs subsidiary of $1,000,000 (the total of the investment was $1,500,000 of which $500,000 is logged as a note receivable). As a result, we had net cash provided by financing activities of $1,318,815.
For the nine months ended September 30, 2025, we made payments on our finance lease obligation of $12,683, had proceeds from the sale of our common stock of $70,000, and we drew down on our line of credit facility for an additional $231,471. As a result, we had net cash provided by financing activities of $288,788.
Plan of Operation
Over the next twelve months, we expect to incur costs and expenses related to:
| · | maintaining our corporate existence, such as annual fees due to the State of Nevada and any other state in which we conduct business; | |
| · | filing periodic reports under the Exchange Act, including filing, accounting and legal fees; | |
| · | operating our business in a proper and ethical manner. |
We expect to incur costs associated with filing reports under the Exchange Act over the next twelve months of approximately $100,000. Costs associated with operating our business based upon current operating expenses are projected to be in the range of $450,000 to $750,000. We anticipate our cost of revenue to be approximately 35% to 45% of revenue. Based upon our performance during 2025 and 2024, and the current year to date, we anticipate that our expenses should be able to be satisfied by our profitability, although this can not be assured. If we are unable to cover our expenses with our gross profit, we may be required to obtain capital from third parties.
Going Concern
The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company generated revenues of $1,019,245 for the nine months ended September 30, 2026, with an associated net loss of $271,922, and at September 30, 2026, the Company has an accumulated deficit of $16,245,404 and working capital of $128,369. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.
Management anticipates continued growth in revenue and plans to utilize the funding resources it has available (i.e., its line of credit facility) as well as the continued identification of adequate sources of funding to provide bridge capital, financing of receivables, and operating capital for continued growth.
The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Off-balance Sheet Arrangements
As of September 30, 2026, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Critical Accounting Policies
Basis of Presentation
The Company's condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that (1) recorded transactions are valid; (2) valid transactions are recorded; and (3) transactions are recorded in the proper period in a timely manner to produce consolidated financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revision of Previously Issued Financials
In connection with the preparation of the Company's financial statements for the three and nine months ended September 30, 2026, management identified an immaterial error in the previously issued financial statements for the three and six months ending June 30, 2026.
Management evaluated the error under SAB Topic 1.M (SAB 99) and SAB Topic 1.N (SAB 108) and concluded that the error was not material to the previously issued financial statements. Accordingly, the Company has revised the financial statements for the three and six months ended June 30, 2026, presented herein to correct the error.
The Company identified an immaterial error in the financial statements related to the allocation of deferred revenue to incurred revenue related to IRB studies (rolled up in "medical procedures" revenues). Initially, the Company amortized the incurred revenue over the portion of the IRB study related to the "treatment phase" of the patients. However, considering that the Company continued to incur costs associated with an option for the study participants to continue their treatment over a "crossover period" post conclusion of the treatment phase, the Company found it more accurate to recognize and amortize the revenue of the IRB study over the period to include both the treatment phase and the optional crossover period.
Going forward, the same methodology will be applied to future IRB studies. The error was previously evaluated and determined not to be material to the Company's financial statements.
After giving effect to this correction during the three and six month ended June 30, 2026, there are no impacts to retained earnings nor shareholder's equity (deficit) as relates to the three and nine months ended September 30, 2026, as the initial IRB that cause this amortization of revenue to come to our attention concluded prior to the end of September 30, 2026.
Therefore, the only impact is to revenue and the net income for the three and six months ended June 30, 2026. The only permanent impact to retained earnings at June 30, 2026, thereby impacting stockholders' equity (deficit) as of June 30, 2026. In addition, the Company carried an additional $96,800 in deferred revenue on its balance sheet at June 30, 2026, to offset the aforementioned adjustments effectively.
ADIA MED, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
|
For the Three Months Ended June 30, 2026 (as reported) |
Topside Adjustment |
For the Three Months Ended June 30, 2026 (revised) |
||||||||||
| Revenue | ||||||||||||
| Sales of supplements | $ | - | $ | - | $ | - | ||||||
| Medical procedures | 329,820 | (96,800 | ) | 233,020 | ||||||||
| Sales of biologics | 151,750 | - | 151,750 | |||||||||
| Services | - | - | - | |||||||||
| Shipping and delivery | 3,815 | - | 3,815 | |||||||||
| Total Revenue | 485,385 | (96,800 | ) | 388,585 | ||||||||
| Cost of Revenue | ||||||||||||
| Supplements | - | - | - | |||||||||
| Procedures | 82,588 | - | 82,588 | |||||||||
| Biologics | 120,217 | - | 120,217 | |||||||||
| Total Cost of Revenue | 202,805 | - | 202,805 | |||||||||
| Gross Profit | 282,580 | (96,800 | ) | 185,780 | ||||||||
| Operating Expenses | ||||||||||||
| General and administrative | 23,175 | - | 23,175 | |||||||||
| Advertising and promotion | 22,436 | - | 22,436 | |||||||||
| Clinical trial fees | 7,175 | - | 7,175 | |||||||||
| Corporate filing fees | 7,723 | - | 7,723 | |||||||||
| Equipment leases | 6,696 | - | 6,696 | |||||||||
| Legal and professional fees | 81,922 | - | 81,922 | |||||||||
| Public relations | 2,480 | - | 2,480 | |||||||||
| Repairs and maintenance | 1,152 | - | 1,152 | |||||||||
| Rent | 19,748 | - | 19,748 | |||||||||
| Research and development | - | - | - | |||||||||
| Salaries and wages | 55,129 | - | 55,129 | |||||||||
| Utilities | 1,672 | - | 1,672 | |||||||||
| Depreciation and amortization | 1,443 | - | 1,443 | |||||||||
| Total Operating Expenses | 230,751 | - | 230,751 | |||||||||
| Income (Loss) from Operations | 51,829 | (96,800 | ) | (44,971 | ) | |||||||
| Other Income (Expense) | ||||||||||||
| Interest income | 375 | - | 375 | |||||||||
| Interest expense - related party | (11,786 | ) | - | (11,786 | ) | |||||||
| Total Other Income (Expense) | (11,411 | ) | - | (11,411 | ) | |||||||
| Net Income (Loss) Before provision for Income Taxes | 40,418 | (96,800 | ) | (56,382 | ) | |||||||
| Provision for Income Taxes | - | - | - | |||||||||
| NET INCOME (LOSS) | $ | 40,418 | $ | (96,800 | ) | $ | (56,382 | ) | ||||
|
For the Six Months Ended June 30, 2026 (as reported) |
Topside Adjustment |
For the Six Months Ended June 30, 2026 (revised) |
||||||||||
| Revenue | ||||||||||||
| Sales of supplements | $ | - | $ | - | $ | - | ||||||
| Medical procedures | 434,670 | (96,800 | ) | 337,870 | ||||||||
| Sales of biologics | 221,525 | - | 221,525 | |||||||||
| Services | - | - | - | |||||||||
| Shipping and delivery | 5,465 | - | 5,465 | |||||||||
| Total Revenue | 661,660 | (96,800 | ) | 564,860 | ||||||||
| Cost of Revenue | ||||||||||||
| Supplements | - | - | - | |||||||||
| Procedures | 153,550 | - | 153,550 | |||||||||
| Biologics | 157,953 | - | 157,953 | |||||||||
| Total Cost of Revenue | 311,503 | - | 311,503 | |||||||||
| Gross Profit | 350,157 | (96,800 | ) | 253,357 | ||||||||
| Operating Expenses | ||||||||||||
| General and administrative | 56,952 | - | 56,952 | |||||||||
| Advertising and promotion | 59,443 | - | 59,443 | |||||||||
| Clinical trial fees | 12,025 | - | 12,025 | |||||||||
| Corporate filing fees | 11,728 | - | 11,728 | |||||||||
| Equipment leases | 13,392 | - | 13,392 | |||||||||
| Legal and professional fees | 160,731 | - | 160,731 | |||||||||
| Public relations | 4,920 | - | 4,920 | |||||||||
| Repairs and maintenance | 2,162 | - | 2,162 | |||||||||
| Rent | 35,931 | - | 35,931 | |||||||||
| Research and development | - | - | - | |||||||||
| Salaries and wages | 87,731 | - | 87,731 | |||||||||
| Utilities | 2,538 | - | 2,538 | |||||||||
| Depreciation and amortization | 2,695 | - | 2,695 | |||||||||
| Total Operating Expenses | 450,248 | - | 450,248 | |||||||||
| Income (Loss) from Operations | (100,091 | ) | (96,800 | ) | (196,891 | ) | ||||||
| Other Income (Expense) | ||||||||||||
| Interest income | 750 | - | 750 | |||||||||
| Interest expense - related party | (22,766 | ) | - | (22,766 | ) | |||||||
| Total Other Income (Expense) | (22,016 | ) | - | (22,016 | ) | |||||||
| Net Income (Loss) Before provision for Income Taxes | (122,107 | ) | (96,800 | ) | (218,907 | ) | ||||||
| Provision for Income Taxes | - | - | - | |||||||||
| NET INCOME (LOSS) | $ | (122,107 | ) | $ | (96,800 | ) | $ | (218,907 | ) | |||
ADIA MED, INC.
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (UNAUDIITED)
| Special 2022 Series A Preferred | Series A Preferred | Series C Preferred | Shares to be issued | |||||||||||||||||||||||||||||
| Shares | Amount ($) | Shares | Amount ($) | Shares | Amount ($) | Shares | Amount ($) | |||||||||||||||||||||||||
| Balance December 31, 2025 | 1 | 1 | - | - | 1,750,000 | 1,750 | 2,875,000 | 152,607 | ||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||
| Balance March 31, 2026 | 1 | 1 | - | - | 1,750,000 | 1,750 | 2,875,000 | 152,607 | ||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||
| Balance June 30, 2026 | 1 | 1 | - | - | 1,750,000 | 1,750 | 2,875,000 | 152,607 | ||||||||||||||||||||||||
(continued)
| Class A Common Stock | Class B Common Stock | Additional Paid-In | Accumulated |
Total Stockholders' Equity |
||||||||||||||||||||||||
| Shares | Amount ($) | Shares | Amount ($) | Capital ($) | Deficit ($) | (Deficit) ($) | ||||||||||||||||||||||
| Balance December 31, 2025 | 94,404,696 | 94,405 | - | - | 15,467,045 | (15,973,482 | ) | (257,674 | ) | |||||||||||||||||||
| Net loss | - | - | - | - | - | (162,525 | ) | (162,525 | ) | |||||||||||||||||||
| Balance March 31, 2026 | 94,404,696 | 94,405 | - | - | 15,467,045 | (16,136,007 | ) | (420,199 | ) | |||||||||||||||||||
| Net loss | - | - | - | - | - | (56,382 | ) | (56,382 | ) | |||||||||||||||||||
| Balance June 30, 2026 | 94,404,696 | 94,405 | - | - | 15,467,045 | (16,192,389 | ) | (476,581 | ) | |||||||||||||||||||
Principles of Consolidation
The condensed consolidated financial statements have been prepared in accordance with GAAP. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (Biolete, LLC, Adia Med of Winter Park, LLC and Adia Labs, LLC). All intercompany balances and transactions have been eliminated.
Cash and Cash Equivalents
The Company accounts for cash and cash equivalents under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 305, "Cash and Cash Equivalents," and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Revenue Recognition
The Company records transactions in accordance with ASU 2014-09, "Revenue from Contracts with Customers" and all subsequent amendments to the ASU (collectively, "ASC 606"). In accordance with ASC 606, revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.
Our operations currently generate revenues from the sale of our biologic products, the performance of medical procedures, sales of ancillary products, shipping and delivery, and other services. During the nine months ended September 30, 2026 and 2025, the Company had revenues of $1,019,245 and $521,958, respectively. Revenue was generated from the following sources:
| September 30, 2026 | September 30, 2025 | |||||||||||||||
| Sales of supplements | $ | - | 0.0% | $ | 3,393 | 0.7% | ||||||||||
| Medical procedures | 576,770 | 56.6% | 198,600 | 38.0% | ||||||||||||
| Sales of biologics | 433,260 | 42.5% | 313,010 | 60.0% | ||||||||||||
| Services | - | - | 2,267 | 0.4% | ||||||||||||
| Shipping and delivery | 9,215 | 0.9% | 4,688 | 0.9% | ||||||||||||
| Total Revenue | $ | 1,019,245 | 100.0% | $ | 521,958 | 100.0% | ||||||||||
Income Taxes and Valuation Allowance
The Company accounts for income taxes under ASC 740, "Income Taxes". Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. All of the Company's deferred tax assets were offset by a full valuation allowance for September 30, 2026 and December 31, 2025.
Financial Instruments
ASC 820, "Fair Value Measurements and Disclosures," defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
| Level 1 - | Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. | |
| Level 2 - | Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. | |
| Level 3 - | Inputs that are both significant to the fair value measurement and unobservable. |
Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2026. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.
The Company does not have any assets or liabilities measured at fair value on a recurring basis.
Related Parties
The Company follows ASC 850-10, "Related Party Disclosures," for the identification of related parties and disclosure of related party transactions. The EO and Director of the Company has provided working capital to the Company on the line of credit facility he has extended to the Company.
Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) principal owners of the Company; c) management of the Company; d) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and e) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.
Material related party transactions are required to be disclosed in the consolidated financial statements, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which statements of operation are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which statements of operations are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.
Loss Contingencies
From time to time the Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the condensed consolidated balance sheet.
Long-lived Assets
Long-lived assets such as fixed assets and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.
Segment Reporting
During the year ended December 31, 2025, the Company had three operating segments: (1) Biolete, (2) Adia Med, and (3) Adia Labs. On September 30, 2025, the Company sold its rights to the Biolete trademarks and all associated assets to Cement Factory, and as a result for the nine months ended September 30, 2026, the Company had two operating segments: (1) Adia Med, and (2) Adia Labs.
|
September 30, 2026 |
December 31, 2025 |
|||||||
| Adia Med assets | $ | 304,751 | $ | 261,208 | ||||
| Adia Labs assets | 1,435,348 | 25,025 | ||||||
| Unallocated corporate assets | 712,888 | 308,593 | ||||||
| Total Assets | $ | 2,452,987 | $ | 594,826 | ||||
The CODM reviews performance based on gross profit (sales less cost of products or services sold), operating profit, and net income (loss). Profitability is important to the Company's ability to grow and expand operations. The Company does not have any operations or sources of revenue outside of the United States. Corporate overhead is not allocated to each segment unless the cost is specifically incurred to support the single segment. This provides the CODM with segment specific costs and profits.
The Company chooses to disclose the following in its segment reporting requirements for the nine months ended September 30, 2026:
|
For the nine months ended September 30, 2026 |
Unallocated | |||||||||||||||||||
| Corporate | ADIA | ADIA | ||||||||||||||||||
| Overhead | Biolete | Med | Labs | Totals | ||||||||||||||||
| Segment Revenue | ||||||||||||||||||||
| Medical procedures | $ | - | $ | - | $ | 576,770 | $ | - | $ | 576,770 | ||||||||||
| Sales of biologics, net of discounts and refunds | - | - | - | 433,260 | 433,260 | |||||||||||||||
| Shipping and delivery | - | - | - | 9,215 | 9,215 | |||||||||||||||
| Total Segment Revenue | - | - | 576,770 | 442,475 | 1,019,245 | |||||||||||||||
| Cost of Revenue | ||||||||||||||||||||
| Cost of goods sold | - | - | 160,674 | 384,233 | 544,907 | |||||||||||||||
| Gross Profit | - | - | 416,096 | 58,242 | 474,338 | |||||||||||||||
| Operating Expenses | ||||||||||||||||||||
| General and administrative | 353,287 | - | 241,517 | 39,732 | 634,536 | |||||||||||||||
| Advertising and promotion | 1,126 | - | 74,717 | - | 75,843 | |||||||||||||||
| Segment Operating Expenses | 354,413 | - | 316,234 | 39,732 | 710,379 | |||||||||||||||
| Segment Profit (Loss) | $ | (354,413 | ) | $ | - | $ | 99,862 | $ | 18,510 | $ | (236,041 | ) | ||||||||
The Company chooses to disclose the following in its segment reporting requirements for the nine months ended September 30, 2025:
|
For the nine months ended September 30, 2025 |
Unallocated | |||||||||||||||||||
| Corporate | ADIA | ADIA | ||||||||||||||||||
| Overhead | Biolete | Med | Labs | Totals | ||||||||||||||||
| Segment Revenue | ||||||||||||||||||||
| Medical procedures | $ | - | $ | - | $ | 198,600 | $ | - | $ | 198,600 | ||||||||||
| Sales of biologics, net of discounts and refunds | - | - | - | 313,010 | 313,010 | |||||||||||||||
| Sales of supplements | - | 3,393 | - | - | 3,393 | |||||||||||||||
| Services | 2,267 | - | - | 2,267 | ||||||||||||||||
| Shipping and delivery | - | - | - | 4,688 | 4,688 | |||||||||||||||
| Total Segment Revenue | 2,267 | 3,393 | 198,600 | 317,698 | 521,958 | |||||||||||||||
| Cost of Revenue | ||||||||||||||||||||
| Cost of goods sold | - | 1,057 | 93,315 | 184,125 | 278,497 | |||||||||||||||
| Gross Profit | 2,267 | 2,336 | 105,285 | 133,573 | 243,461 | |||||||||||||||
| Operating Expenses | ||||||||||||||||||||
| General and administrative | 182,085 | 2,226 | 147,902 | 4,198 | 336,411 | |||||||||||||||
| Advertising and promotion | 25,349 | 67 | 24,497 | 5,066 | 54,979 | |||||||||||||||
| Segment Operating Expenses | 207,434 | 2,293 | 172,399 | 9,264 | 391,390 | |||||||||||||||
| Segment Profit (Loss) | $ | (205,167 | ) | $ | 42 | $ | (67,114 | ) | $ | 124,309 | $ | (147,929 | ) | |||||||
Stock-Based Compensation
FASB ASC 718 "Compensation - Stock Compensation," prescribes accounting and reporting standards for all stock-based payments award to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity's past practices or stated policies. If a present obligation exists, the transaction should be recognized as a liability; otherwise, the transaction should be recognized as equity.
The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50 "Equity - Based Payments to Non-Employees." Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. For the three and nine months ended September 30, 2026 and 2025, the Company had no share-based compensation.
Recently Issued Accounting Pronouncements
We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. For the year ended December 31, 2025, we adopted the ASU 2023-09, "Income Taxes (Topic 740) Improvement to Income Tax Disclosure", to appropriately reconcile to specific tax rate provisions.